Immutep Reported Late Wednesday: First Patient Dosed In AIPAC-003 Phase II/III Trial For Metastatic Breast Cancer
Portfolio Pulse from Charles Gross
Immutep Limited has announced the first patient has been enrolled and safely dosed in its Phase II/III AIPAC-003 trial for metastatic breast cancer at a European clinical site.
May 25, 2023 | 8:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep has successfully enrolled and dosed the first patient in its Phase II/III AIPAC-003 trial for metastatic breast cancer.
The successful enrollment and dosing of the first patient in Immutep's AIPAC-003 trial is a positive development for the company. This progress in their clinical trial may lead to increased investor interest and a potential short-term positive impact on IMMP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100